Glenmark Pharma receives tentative ANDA approval for Calcipotriene and Betamethasone Dipropionate foam

The drug is the generic version of Enstilar Foam, 0.005%|0.064%, of Leo Pharma AS
Glenmark Pharma receives tentative ANDA approval for Calcipotriene and Betamethasone Dipropionate foam

Glenmark Pharma has been granted tentative approval by the US Food and Drug Administration (FDA) for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064%, the generic version of Enstilar Foam, 0.005%|0.064%, of Leo Pharma AS.

According to IQVIA sales data for the 12-month period ending March 2022, the Enstilar Foam 0.005% |0.064% market achieved annual sales of approximately $115.2 million.

ANDA approvalGlenmark PharmaLeo PharmaUS FDA approval
Comments (0)
Add Comment